Inclusion Criteria:

- Histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage T1
- T3 (AJCC 6th Edition, see Appendix II), NX/N0, M0, following prior prostate
radiotherapy.

- Karnofsky performance status >80.

- Greater than 5 year life expectancy

- Greater than 2 years since the original course of radiotherapy.

- Absence of distant metastases by radiologic or pathologic assessment.

- Absence of lymph node involvement by radiologic or pathologic assessment.

- Patients must sign a study-specific informed consent form prior to study entry.

Exclusion Criteria:

- Stage T4 disease (AJCC 6th Edition, see Appendix II).

- Less than 2 years since the original course of radiotherapy.

- Lymph node involvement (N1).

- Evidence of distant metastases (M1).

- Radical surgery for carcinoma of the prostate

- Previous or concurrent cancers other than basal, in situ, or squamous cell skin
cancers unless disease-free for ≥ 5 years.

- Major medical or psychiatric illness, which in the investigator's opinion, would
prevent completion of treatment and would interfere with follow-up.

- History of inflammatory bowel disease

- Late GI or GU Morbidity > Grade 1 from the prior course of radiotherapy